CHRONIC MYELOMONOCYTIC LEUKEMIA
Clinical trials for CHRONIC MYELOMONOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new CHRONIC MYELOMONOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a drug combo boost red blood cells in bone marrow disease patients?
Disease control OngoingThis study tests whether adding a second drug (epoetin alfa) to lenalidomide helps people with myelodysplastic syndrome (MDS) and anemia more than lenalidomide alone. About 247 adults with low- or intermediate-risk MDS and low red blood cell counts took part. The main goal was to…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:36 UTC
-
New drug cocktail shows promise for Hard-to-Treat leukemia
Disease control OngoingThis study is testing a combination of three drugs (azacitidine, venetoclax, and pevonedistat) in adults with a newly diagnosed, aggressive form of acute myeloid leukemia (AML) that is related to prior cancer treatment or other blood disorders. The goal is to find the best dose a…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:35 UTC
-
Targeted therapy duo takes aim at hard-to-treat blood cancer
Disease control OngoingThis study tests a combination of two drugs—tagraxofusp and decitabine—for people with chronic myelomonocytic leukemia or related high-risk blood disorders. Tagraxofusp delivers a toxin directly to cancer cells, while decitabine is a chemotherapy that stops cancer growth. The goa…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:34 UTC
-
Tailored transplants for seniors: can a simple assessment improve outcomes?
Disease control OngoingThis study looks at whether a geriatric assessment—checking thinking, mobility, mood, and nutrition—can help doctors choose the best transplant approach for people aged 60 and older with certain blood cancers. The goal is to lower the risk of serious side effects and improve qual…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:33 UTC
-
Could a new combo boost remission in tough leukemia?
Disease control OngoingThis study tests whether adding the drug pomalidomide to standard chemotherapy helps people with a certain type of acute myeloid leukemia (AML) that is linked to prior blood disorders or cancer treatment. About 50 adults with newly diagnosed AML will be randomly assigned to get e…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:31 UTC
-
New chemo combo aims to keep leukemia from returning after transplant
Disease control OngoingThis study tests whether giving two chemotherapy drugs, clofarabine and melphalan, before a donor stem cell transplant can help prevent leukemia or myelodysplasia from coming back. The trial includes 72 adults whose cancer is in remission or who have high-risk myelodysplastic syn…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 04:30 UTC
-
New combo therapy battle for blood cancer patients
Disease control OngoingThis study tests whether adding another drug (lenalidomide or vorinostat) to the standard chemotherapy azacitidine works better than azacitidine alone for people with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). About 282 adults with thes…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:15 UTC
-
New antibody combo targets tough blood cancers
Disease control OngoingThis study tests a new drug called bexmarilimab, given with standard treatments, for people with certain blood cancers (MDS, CMML, or AML). The first part finds a safe dose, and the second part checks if the combination helps control the cancer. About 181 adults will take part.
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Faron Pharmaceuticals Ltd • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New hope for rare leukemia: drug aims to control disease and delay progression
Disease control OngoingThis study tests whether the drug ruxolitinib can help people with chronic myelomonocytic leukemia (CMML), a rare blood cancer. About 29 adults will receive the drug to see if it improves blood counts, shrinks the cancer, or keeps it stable. The goal is to control the disease and…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New drug combo targets Hard-to-Treat blood cancers
Disease control OngoingThis study tests a combination of two drugs, azacitidine and quizartinib, for adults with myelodysplastic syndromes or related blood cancers that have specific gene changes (FLT3 or CBL). The goal is to find the best dose and see how well the drugs control the cancer. About 30 pe…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Could a pill prevent relapse after transplant for blood cancer?
Disease control OngoingThis early-phase study tests whether the oral drug Inqovi (decitabine/cedazuridine) can safely reduce the chance of cancer returning after a stem cell transplant in people with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML). About 22 adults who have had …
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New CMV strategy aims to protect stem cell transplant patients from dangerous infection
Disease control OngoingThis study looks at a modified approach to prevent and treat cytomegalovirus (CMV) infection in people who have had a donor stem cell transplant for blood cancers or disorders. About 153 participants are involved, and the goal is to see if changing when and how anti-CMV drugs are…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New combo therapy targets relapsed blood cancers after transplant
Disease control OngoingThis early-phase study tests a new treatment for people whose blood cancer (like AML or MDS) has returned after a donor stem cell transplant. The treatment combines a special type of donor immune cell infusion with an immunotherapy drug called ipilimumab. The main goal is to find…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Could a targeted drug boost chemo for tough blood cancers?
Disease control OngoingThis study tests whether adding the experimental drug veliparib to standard chemotherapy (topotecan and carboplatin) helps people with advanced myeloproliferative disorders, acute myeloid leukemia, or chronic myelomonocytic leukemia. About 25 adults took part. The goal was to see…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Blood cancer drug ASTX727 extended access trial opens for prior beneficiaries
Disease control ENROLLING_BY_INVITATIONThis study provides continued treatment with the oral drug ASTX727 for adults with acute myeloid leukemia, chronic myelomonocytic leukemia, or myelodysplastic syndromes who were already benefiting from it in an earlier trial. The main goal is to gather long-term safety informatio…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
New drug combo targets tough blood cancers
Disease control OngoingThis study tests a combination of two drugs, guadecitabine and atezolizumab, in adults with myelodysplastic syndrome or chronic myelomonocytic leukemia that has spread, returned, or not responded to prior treatment. The goal is to find the best dose and see how well the drugs wor…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
New drug combo shows promise for blood cancers in early trial
Disease control OngoingThis study tested a combination of two drugs, vorinostat and azacitidine, in 135 people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal was to find the safest dose and see how well the drugs work together to stop cancer cell growth. Participants rece…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:03 UTC
-
New combo therapy shows promise for tough blood cancers
Disease control OngoingThis study tests a combination of two chemotherapy drugs (CPX-351) plus a targeted antibody (gemtuzumab ozogamicin) in about 50 adults whose acute myeloid leukemia or high-risk myelodysplastic syndrome has returned or not responded to prior treatment. The goal is to see if the co…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 08, 2026 12:03 UTC
-
New drug combo aims to improve leukemia treatment
Disease control OngoingThis phase 2 trial tests whether adding venetoclax to ASTX727 (a two-drug pill) works better than ASTX727 alone for adults with chronic myelomonocytic leukemia or related bone marrow cancers with excess blasts. About 132 participants will receive either the combination or ASTX727…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 07, 2026 18:42 UTC
-
Lower drug dose after transplant may cut infections without losing protection
Disease control OngoingThis study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections while still preventing graft-versus-host disease (a condition where donor cells attack the patient's body). About 3…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated May 06, 2026 16:15 UTC
-
Promising combo targets tough blood cancers in early trial
Disease control OngoingThis study tests two drugs, venetoclax and ASTX727, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) who have not had treatment before. The goal is to find the best dose and see how well the combination controls the cancer. About 5…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 04, 2026 16:17 UTC
-
Study on calprotectin's role in severe COVID-19 and blood cancers withdrawn before starting
Knowledge-focused TerminatedThis study was designed to learn how the protein calprotectin might change blood stem cells in people with severe COVID-19 or certain blood cancers. Researchers planned to compare stem cells from patients and healthy volunteers in the lab. However, the study was withdrawn before …
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated May 17, 2026 04:32 UTC